Pharma Report on High Mobility Group Protein B1 – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/high-mobility-group-protein-b1-pipeline-review-h2-2020-645875.html

High Mobility Group Protein B1 – Pipeline Review, H2 2020

Summary

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) – High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus.

High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 10 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Cardiovascular, Central Nervous System, Gastrointestinal, Oncology, Dermatology, Musculoskeletal Disorders, Other Diseases and Respiratory which include indications Parkinson’s Disease, Sepsis, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Brain (Head) Trauma, Cardiomyopathy, Cerebral Infarction (Brain Infarction), Chronic Liver Disease, Coronavirus Disease 2019 (COVID-19), Dilated Cardiomyopathy, Epidermolysis Bullosa, Epilepsy, Influenzavirus A Infections, Ischemic Cardiomyopathy, Liver Diseases, Myelodysplastic Syndrome, Osteoarthritis, Refractory Acute Myeloid Leukemia and Stroke.

The latest report High Mobility Group Protein B1 – Pipeline Review, H2 2020, outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
– The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects
– The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics

Reasons to Buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned:
Afecta Pharmaceuticals Inc
Affibody AB
Chimerix Inc
Shionogi & Co Ltd
TheraSource LLC


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645875

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.